You have not yet registered? Get your account for free.
Forgot Password? We will send you a reset link
22 October 2024
Half-yearly financial statements 2024
29 April 2024
Annual financial statements 2023
30 August 2023
Half-yearly financial statements 2023
5 May 2023
Annual financial statements 2022
28 October 2022
Half-yearly financial statements 2022
18 May 2022
Annual financial statements 2021
21 September 2021
Half-yearly financial statements 2021
17 May 2021
Annual financial statements 2020
29 September 2020
Half-yearly financial statements 2020
25 May 2020
Annual financial statements 2019
24 September 2019
Halbjahresabschluss 2019
Half-yearly financial statements 2019
15 May 2019
Annual financial statements 2018
17 September 2018
Halbjahresabschluss 2018
28 May 2018
Jahresabschluss 2017
6 October 2017
Halbjahresabschluss 2017
24 May 2017
Jahresabschluss 2016
20 September 2016
Half-yearly financial statements 2016
4 November 2024
Formycon applies for admission to the Prime Standard of the Frankfurt Stock Exchange
16 October 2024
Formycon published results of analytical similarity study of biosimilar candidate FYB206 and Keytruda® in peer-reviewed journal Drugs in R&D
30 September 2024
Formycon and Fresenius Kabi receive FDA approval for FYB202/ OtulfiTM (ustekinumab-aauz)
27 September 2024
FDA grants approval for Stelara® Biosimilar FYB202/OtulfiTM (ustekinumab-aauz)
Formycon and Fresenius Kabi receive European Commission approval for FYB202/Otulfi® (ustekinumab) for the treatment of serious inflammatory diseases
17 September 2024
Formycon will present clinical data on its ustekinumab biosimilar candidate FYB202 at the EADV Congress in Amsterdam and the UEG Week in Vienna
25
Nov 24
Analysts’ Conference
Nov
2024
Press Release – quarterly statement (call-date Q3)
